Anti-MARV GP/Envelope glycoprotein Antibody (2D8)

Catalog No.

RVV24308

Species reactivity

Marburg virus (MARV)

Host species

Human

Isotype

IgG1, kappa

Clonality

Monoclonal

Applications

ELISA, Neutralization

Target

GP, Envelope glycoprotein

Concentration

2.32 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q1PDC7

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

2D8

Note

For research use only.

Inhibition of Marburg virus budding by nonneutralizing antibodies to the envelope glycoprotein., PMID:23035224

Novel mutations in Marburg virus glycoprotein associated with viral evasion from antibody mediated immune pressure., PMID:23288419

Mapping of conserved and species-specific antibody epitopes on the Ebola virus nucleoprotein., PMID:23702199

Determination of specific antibody responses to the six species of ebola and Marburg viruses by multiplexed protein microarrays., PMID:25230936

Cell entry by a novel European filovirus requires host endosomal cysteine proteases and Niemann-Pick C1., PMID:25310500

Cross-protection conferred by filovirus virus-like particles containing trimeric hybrid glycoprotein., PMID:25514232

Mechanism of human antibody-mediated neutralization of Marburg virus., PMID:25723164

Structural basis for Marburg virus neutralization by a cross-reactive human antibody., PMID:25723165

A Single-Vector, Single-Injection Trivalent Filovirus Vaccine: Proof of Concept Study in Outbred Guinea Pigs., PMID:25957964

Codon-optimized filovirus DNA vaccines delivered by intramuscular electroporation protect cynomolgus macaques from lethal Ebola and Marburg virus challenges., PMID:25996997

Preclinical Development of Inactivated Rabies Virus-Based Polyvalent Vaccine Against Rabies and Filoviruses., PMID:26063224

Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs., PMID:26115029

Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein., PMID:26468532

Virus-Like Particle Vaccination Protects Nonhuman Primates from Lethal Aerosol Exposure with Marburgvirus (VLP Vaccination Protects Macaques against Aerosol Challenges)., PMID:27070636

Human Survivors of Disease Outbreaks Caused by Ebola or Marburg Virus Exhibit Cross-Reactive and Long-Lived Antibody Responses., PMID:27335383

Toremifene interacts with and destabilizes the Ebola virus glycoprotein., PMID:27362232

Generation and characterization of protective antibodies to Marburg virus., PMID:28287337

Marburg virus-like particles produced in insect cells induce neutralizing antibodies in rhesus macaques., PMID:28402024

Marburg virus-like particles by co-expression of glycoprotein and matrix protein in insect cells induces immune responses in mice., PMID:29070075

Single-Dose Trivalent VesiculoVax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge., PMID:29142131

A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates., PMID:29462200

Pan-Filovirus Serum Neutralizing Antibodies in a Subset of Congolese Ebolavirus Infection Survivors., PMID:30107445

Identity and validity of conserved B cell epitopes of filovirus glycoprotein: towards rapid diagnostic testing for Ebola and possibly Marburg virus disease., PMID:30285648

A Recombinant Rabies Virus Expressing the Marburg Virus Glycoprotein Is Dependent upon Antibody-Mediated Cellular Cytotoxicity for Protection against Marburg Virus Disease in a Murine Model., PMID:30567978

Immune correlates of postexposure vaccine protection against Marburg virus., PMID:32080323

Non-neutralizing Antibodies from a Marburg Infection Survivor Mediate Protection by Fc-Effector Functions and by Enhancing Efficacy of Other Antibodies., PMID:32320678

A Surrogate Animal Model for Screening of Ebola and Marburg Glycoprotein-Targeting Drugs Using Pseudotyped Vesicular Stomatitis Viruses., PMID:32842671

Modified vaccinia Ankara vaccine expressing Marburg virus-like particles protects guinea pigs from lethal Marburg virus infection., PMID:32922962

Discovery of Marburg virus neutralizing antibodies from virus-naïve human antibody repertoires using large-scale structural predictions., PMID:33229516

Prototype of a DNA Vaccine against Marburg Virus., PMID:33713231

Comparative analyses of small molecule and antibody inhibition on glycoprotein-mediated entry of Měnglà virus with other filoviruses., PMID:35332563

A highly attenuated Vesiculovax vaccine rapidly protects nonhuman primates against lethal Marburg virus challenge., PMID:35622847

Ligand-based design of peptide entry inhibitors targeting the endosomal receptor binding site of filoviruses., PMID:36007601

Assays for the Evaluation of the Immune Response to Marburg and Ebola Sudan Vaccination-Filovirus Animal Nonclinical Group Anti-Marburg Virus Glycoprotein Immunoglobulin G Enzyme-Linked Immunosorbent Assay and a Pseudovirion Neutralization Assay., PMID:36016099

Protection against Marburg Virus and Sudan Virus in NHP by an Adenovector-Based Trivalent Vaccine Regimen Is Correlated to Humoral Immune Response Levels., PMID:36016151

Immune Correlates of Protection from Filovirus Efficacy Studies in Non-Human Primates., PMID:36016226

First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study., PMID:36197845

Nonhuman Primates Are Protected against Marburg Virus Disease by Vaccination with a Vesicular Stomatitis Virus Vector-Based Vaccine Prepared under Conditions to Allow Advancement to Human Clinical Trials., PMID:36298451

A rabies virus-vectored vaccine expressing two copies of the Marburg virus glycoprotein gene induced neutralizing antibodies against Marburg virus in humanized mice., PMID:36453198

Preexisting Immunity Does Not Prevent Efficacy of Vesicular Stomatitis Virus-Based Filovirus Vaccines in Nonhuman Primates., PMID:37290042

Thermostable bivalent filovirus vaccine protects against severe and lethal Sudan ebolavirus and marburgvirus infection., PMID:38158300

Production and Purification of Filovirus Glycoproteins., PMID:38315357

A novel MARV glycoprotein-specific antibody with potentials of broad-spectrum neutralization to filovirus., PMID:38526940

Divergent antibody recognition profiles are generated by protective mRNA vaccines against Marburg and Ravn viruses., PMID:38585993

Rational design of self-amplifying virus-like vesicles with Ebola virus glycoprotein as vaccines., PMID:39217415

Longitudinal proteome-wide antibody profiling in Marburg virus survivors identifies wing domain immunogen for vaccine design., PMID:39285186

Serological Evidence of Potential Marburg Virus Circulation in Livestock and Dogs in Ghana., PMID:39599470

A surrogate BSL2-compliant infection model recapitulating key aspects of human Marburg virus disease., PMID:39745141

Rapid Development of Modified Vaccinia Virus Ankara (MVA)-Based Vaccine Candidates Against Marburg Virus Suitable for Clinical Use in Humans., PMID:39771978

Potent neutralization of Marburg virus by a vaccine-elicited monoclonal antibody., PMID:40463027

Document Download

Anti-MARV GP/Envelope glycoprotein Antibody (2D8).pdf